OnKure Therapeutics, Inc. OKUR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $458K-57.4% | $622K-50.5% | $802K+1,923% | $934K+358% | $1.08M+263% | ||
| $458K-57.4% | $628K-52.2% | $804K+362% | $934K+306% | $1.08M+264% | ||
| $11.71M-10.0% | $10.72M-25.4% | $11.92M+17.8% | $12.61M+17.3% | $13.01M+51.9% | ||
| $3.91M-2.0% | $3.41M-21.5% | $3.59M+157% | $3.71M+3.3% | $3.99M+215% | ||
| $15.62M-8.1% | $14.13M-24.5% | $15.5M+34.7% | $16.32M+13.8% | $17M+72.9% | ||
| $15.62M-8.1% | $14.13M-24.5% | $15.5M+34.7% | $16.32M+13.8% | $17M+72.9% | ||
| -$15.62M+8.1% | -$14.13M+24.5% | -$15.5M-34.7% | -$16.32M-13.8% | -$17M-72.9% | ||
| -$15.16M+4.8% | -$13.5M+22.6% | -$14.7M-27.2% | -$15.39M-8.8% | -$15.93M-67.0% | ||
| -$1.11+6.7% | -$0.99— | -$1.09+97.0% | -$1.14+97.5% | -$1.19+96.1% | ||
| -$1.11+6.7% | -$0.99— | -$1.09+97.0% | -$1.14+97.5% | -$1.19+96.1% | ||
| 13.7M+1.9% | 13.5M+292% | 13.5M+4,180% | 13.5M+4,182% | 13.4M+4,175% | ||
| 13.7M+1.9% | 13.5M+292% | 13.5M+4,180% | 13.5M+4,182% | 13.4M+4,175% | ||
| $458K-57.4% | $622K-50.5% | $802K+1,923% | $934K+358% | $1.08M+263% | ||
| $458K-57.4% | $628K-52.2% | $804K+362% | $934K+306% | $1.08M+264% | ||
| -$15.62M+8.1% | -$14.13M+24.5% | -$15.5M-34.7% | -$16.32M-13.8% | -$17M-72.9% | ||
| -$15.51M+8.1% | -$14.02M+24.5% | -$15.39M-35.1% | -$16.21M-13.9% | -$16.88M-73.7% | ||
| -$15.51M+8.1% | -$14.02M+24.5% | -$15.39M-35.1% | -$16.21M-13.9% | -$16.88M-73.7% | ||
| -$15.62M+8.1% | -$14.13M+24.5% | -$15.5M-34.7% | -$16.32M-13.8% | -$17M-72.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is OnKure Therapeutics, Inc. profitable?
- OnKure Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.7M over the trailing twelve months.
- What is OnKure Therapeutics, Inc.'s earnings per share?
- OnKure Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does OnKure Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.